Evidence map›Paper›PMID 37330456›Full record

ArticleCurrent medical science2023

Donor-derived CD19 CAR-T Cells versus Chemotherapy Plus Donor Lymphocyte Infusion for Treatment of Recurrent CD19-positive B-ALL After Allogeneic Hematopoietic Stem Cell Transplantation.

Xu Tan, Xiao-Qi Wang, Cheng Zhang, Xian-Lan Zhao, Han Yao, Guo Chen, Ying-Ying Ma, Qin Wen, Lei Gao, Li Gao and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.6field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Xu Tan *Department of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xiao-Qi Wang *Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Cheng Zhang *Medical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Xian-Lan ZhaoMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Han YaoMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Guo ChenMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Ying-Ying MaMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Qin WenMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Lei GaoMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Li GaoMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Pei-Yan KongMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China.
Yan ShenDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xi ZhangMedical Center of Hematology, Xinqiao Hospital, State Key Laboratory of Trauma, Burns and Cobmined Injury, Army Medical University, Chongqing, 400037, China. zhangxxi@sina.com.
Shi-Feng LouDepartment of Hematology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China. 13508331213@163.com.
Army Medical University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThis study aimed to compare the efficacy of anti-CD19 chimeric antigen receptor T cells (CAR-T cells) versus chemotherapy plus donor lymphocyte infusion (chemo-DLI) for treating relapsed CD19-positive B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).

methodsClinical data of 43 patients with B-ALL who relapsed after allo-HSCT were retrospectively analyzed. Twenty-two patients were treated with CAR-T cells (CAR-T group), and 21 with chemotherapy plus DLI (chemo-DLI group). The complete remission (CR) and minimal residual disease (MRD)-negative CR rates, leukemia-free survival (LFS) rate, overall survival (OS) rate, and incidence of acute graft-versus-host disease (aGVHD), cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) were compared between the two groups.

resultsThe CR and MRD-negative CR rates in the CAR-T group (77.3% and 61.5%) were significantly higher than those in the chemo-DLI group (38.1% and 23.8%) (P=0.008 and P=0.003). The 1- and 2-year LFS rates in the CAR-T group were superior to those in the chemo-DLI group: 54.5% and 50.0% vs. 9.5% and 4.8% (P=0.0001 and P=0.00004). The 1- and 2-year OS rates in the CAR-T versus chemo-DLI group were 59.1% and 54.5% vs. 19% and 9.5% (P=0.011 and P=0.003). Six patients (28.6%) with grade 2-4 aGVHD were identified in the chemo-DLI group. Two patients (9.1%) in the CAR-T group developed grade 1-2 aGVHD. Nineteen patients (86.4%) developed CRS in the CAR-T group, comprising grade 1-2 CRS in 13 patients (59.1%) and grade 3 CRS in 6 patients (27.3%). Two patients (9.1%) developed grade 1-2 ICANS.

conclusionDonor-derived anti-CD19 CAR-T-cell therapy may be better, safer, and more effective than chemo-DLI for B-ALL patients who relapse after allo-HSCT.

Indexed as

Hematopoietic Stem Cell TransplantationImmunotherapy, AdoptivePrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenT-LymphocytesAcute DiseaseAntigens, CD19Chronic DiseaseHumansLymphocytesNeurotoxicity SyndromesRecurrenceRetrospective StudiesAntigens, CD19cell-associated neurotoxicityReceptors, Chimeric AntigenCD19-positive B-cell acute lymphoblastic leukemiachemo-donor lymphocyte infusiondonor-derived CD19 chimeric antigen receptor T cellsrelapse

Identifiers

PMID37330456
OpenAlexW4381051770

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.